Nicole Sandford

Nicole Sandford, listed as chief executive, appears in our data through filings on Aspira Women's Health Inc. shares, published by SEC (Form 4). We count 13 filings; the first trade dates from 19 March 2021 and the latest from 9 July 2024.

Purchases make up the whole of the open-market record (6 purchases, €154k). The totals exclude 2 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 7 share grants. In 2024 alone, the filings show 2 purchases and no sales.

A typical purchase (the median) is worth €33k. Clusters matter here: 1 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 9 July 2024, the filings show a share grant in Aspira Women's Health Inc. The clock since the last published purchase (3 June 2024) now reads 889 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.